Microbiome Restoration Therapy / FMT
Faecal microbiota transplantation (FMT) transfers processed donor microbiota with the aim of changing the recipient's gut microbial ecosystem. Evidence is indication-specific: it is strongest in recurrent Clostridioides difficile infection, while many other proposed uses remain investigational, inconsistent or dependent on specialist protocols.
The gut microbiome is an important and rapidly evolving area of medicine. The science is real and genuinely interesting; this page explains where current evidence is strongest, where it is still emerging, and how microbiome-directed care should be considered responsibly.
FMT is not a universal “gut reset”
The gut microbiome is associated with many aspects of health, but association does not prove that changing the microbiome will treat every linked condition. Claims about “restoring balance,” “root-cause healing” or treating dozens of unrelated diseases can overstate current clinical evidence.
The clinical question should be specific: what condition is being treated, what evidence supports FMT or another microbiome-directed intervention for that condition, and what conventional investigations or treatments remain necessary?
There is also a causal direction problem that rarely gets mentioned. Many studies show that people with a given condition have a different microbiome from those without it. That finding is compatible with the microbiome causing the condition, the condition altering the microbiome, or both being downstream of diet, medication or inflammation. Marketing routinely presents the first interpretation as though the other two had been excluded.
Where the evidence differs
Recurrent C. difficile infection
This is the best-established clinical context for FMT, particularly after recurrent infection where standard antibiotic strategies have not provided durable control. Management should remain coordinated with the appropriate medical or gastroenterology team.
Inflammatory bowel disease
Research exists in ulcerative colitis and other inflammatory bowel disease settings, but results, protocols and patient selection vary. FMT is not a routine substitute for established IBD therapy.
IBS and functional gut symptoms
Studies are mixed. Improvement is not guaranteed, and symptoms such as bleeding, weight loss, anaemia, persistent diarrhoea or nocturnal symptoms need appropriate investigation.
Metabolic conditions
Microbiome research in obesity, insulin resistance and metabolic disease is active, but clinical use outside research or specialist protocols should not be presented as established treatment.
Neurological or psychiatric conditions
Gut-brain research is scientifically interesting, but this does not establish FMT as a proven treatment for autism, depression, anxiety, Parkinson's disease or other neurological conditions.
General “wellness”
Using donor microbiota purely to improve energy, immunity, longevity or general wellbeing lacks the same level of evidence as indication-based medical use.
| Proposed use | Where the evidence actually sits |
|---|---|
| Recurrent C. difficile infection | Well supported. The one indication with strong, consistent trial evidence. |
| Ulcerative colitis | Genuine research interest; protocols and results vary. Not a replacement for established therapy. |
| Irritable bowel syndrome | Mixed and inconsistent. Some trials positive, others negative, including against placebo. |
| Obesity and metabolic disease | Active research. Not established clinical treatment. |
| Autism | Small preliminary studies only. Should not be marketed as treatment, particularly for children. |
| Depression, anxiety, Parkinson's | Mechanistically interesting, clinically unproven. |
| Autoimmune disease generally | Not established. Established immunological treatment should not be displaced. |
| Energy, immunity, longevity, “detox” | No meaningful evidence. This is where the marketing is, and where the risk-benefit is worst. |
Read the first row and the last row together. The same procedure carries a very different justification depending on why it is being done.
Before considering microbiome therapy
- Clarify the diagnosis rather than treating “dysbiosis” as a stand-alone explanation for every symptom.
- Review recent antibiotics, infections, travel, diet, medications and gastrointestinal history.
- Assess red flags that may require endoscopy, imaging, stool studies, blood tests or specialist review.
- Consider whether established treatments have been tried and optimized.
- Discuss immune suppression, pregnancy, major comorbidities and infection risk.
Donor screening is central to safety
Donor screening commonly involves detailed health and exposure history plus laboratory testing for transmissible pathogens. Screening protocols evolve as new infectious risks emerge, so a static marketing checklist should not be treated as sufficient assurance.
The provenance of donor material, processing standards and clinical governance matter as much as the route of administration.
Do not attempt this at home
Home FMT using material from a friend or relative appears in online communities and is genuinely dangerous. Informal donors are not screened for the transmissible infections that formal protocols test for, and an apparently healthy donor can carry organisms that cause serious illness in a recipient — particularly one who is unwell or immunosuppressed. If this seems like a reasonable option because formal access is difficult, that is worth discussing with a doctor rather than acting on.
Regulation and access can change
FMT and microbiome-derived products sit in a rapidly evolving clinical and regulatory area. The permitted route, indication, product classification, donor source and oversight requirements may differ by jurisdiction and can change over time.
For that reason, Aquila does not use this page to promise that a particular FMT product, route or off-label indication is always available. Current access and suitability should be confirmed during consultation and, where needed, with the relevant specialist or facility.
On stool microbiome test kits
Direct-to-consumer stool tests that report your bacterial composition and grade it against an “optimal” profile are widely sold. The underlying sequencing is real, but the interpretation layered on top generally is not: there is no established definition of a healthy microbiome to compare you against, results vary substantially between laboratories and even between samples from the same person, and the supplement or diet recommendations produced are usually not validated against clinical outcomes.
A report describing your gut as inflamed, imbalanced or deficient can be alarming without being diagnostic. If a test result is what brought you here, bring it — but the symptoms and history will carry more weight than the printout.
What the evidence does support
The least commercial answer is also the best supported one. Dietary fibre diversity, adequate plant variety, limiting unnecessary antibiotics, and treating the underlying condition where one exists have better evidence for gut health than any purchased intervention.
Specific probiotic strains have evidence for specific situations — certain antibiotic-associated diarrhoea contexts, for instance — but that is strain-specific and indication-specific rather than a general case for taking probiotics indefinitely.
Possible risks
Infection transmission
Screening reduces but cannot eliminate infectious risk, and serious transmission events have been reported.
GI symptoms
Bloating, cramps, diarrhoea, constipation, nausea or other gastrointestinal symptoms can occur.
Procedure-related risk
Risk depends on delivery route. Endoscopic or tube-based administration has different risks from oral preparations.
Uncertain long-term effects
Changing a complex microbial ecosystem may have effects that are not fully predictable, particularly outside well-studied indications.
Delayed diagnosis
Attributing symptoms to “microbiome imbalance” can delay diagnosis of inflammatory, infectious, malignant or other medical disease.
Drug and immune context
Antibiotics, immunosuppressants and major illness can materially affect safety and treatment planning.
Frequently asked questions
Is FMT proven for IBS?
Evidence is mixed and it is not a guaranteed or universal treatment for IBS. Patient selection and exclusion of other disease remain important.
Can FMT treat autoimmune disease or autism?
These are areas of research, not established general indications that should be marketed as proven treatment.
Is donor screening enough to make FMT risk-free?
No. Screening is essential but cannot remove all biological and procedural risk, and serious transmission events have occurred.
Do I need a colonoscopy?
Not every microbiome assessment requires colonoscopy, but some symptoms or diagnoses may require endoscopic investigation. The need depends on the clinical problem, not on marketing preference.
Is FMT currently available for my condition?
That depends on the indication, current regulatory pathway, product or donor source, specialist involvement and facility capability. Availability should be confirmed at the time of assessment.
Which indication actually has strong evidence?
Recurrent C. difficile infection. It is the one use with consistent trial support, and it is a very different proposition from wellness use.
Does an altered microbiome in a disease mean it caused the disease?
No. It is equally compatible with the disease altering the microbiome, or both following from diet, medication or inflammation. Marketing tends to assume causation that has not been demonstrated.
Are stool microbiome test kits worth buying?
The sequencing is real but the interpretation generally is not validated. There is no agreed healthy reference profile, results vary between labs and samples, and the resulting supplement advice is rarely tested against outcomes.
My test said my gut is inflamed and imbalanced — should I worry?
Such reports can be alarming without being diagnostic. Bring the result, but your symptoms and history will carry more weight than the printout.
Can I do FMT at home with a healthy friend as donor?
No — this is genuinely dangerous. Informal donors are not screened for transmissible infections, and an apparently healthy person can carry organisms causing serious illness in a recipient.
What actually helps gut health with good evidence?
Dietary fibre and plant diversity, avoiding unnecessary antibiotics, and treating any underlying condition. Unglamorous, and better supported than purchased interventions.
Should I take a probiotic?
Evidence is strain-specific and indication-specific rather than general. Certain strains help in certain situations; taking any probiotic indefinitely is not well supported.
What symptoms mean I should be investigated instead?
Rectal bleeding, unintentional weight loss, anaemia, difficulty swallowing, an abdominal mass, symptoms waking you at night, or new persistent bowel change — especially over 45 or with a family history of bowel cancer.
Can it help with bloating?
Bloating has many causes including coeliac disease, lactose intolerance, medication effects and functional disorders. Identifying the cause matters more than reaching for a microbiome intervention.
Is this safe if I am immunosuppressed?
It requires particular caution. Immunosuppression materially changes the infection risk and must form part of the assessment.
Can it help after a long course of antibiotics?
The gut microbiome generally recovers substantially on its own over time. Where symptoms persist, assessment matters more than assuming permanent damage.
How quickly would I know if it worked?
That depends entirely on the indication, which is another reason a defined clinical goal should be set before treatment rather than after.
Does “detox” describe anything real here?
Not in this context. It is a marketing term rather than a physiological process the gut requires help with.
Is microbiome therapy claimable under MediSave or insurance in Singapore?
Coverage depends on the indication and policy, and wellness use is generally not covered. Check directly with your insurer.
Where is Aquila Medical Center?
Aquila Medical Center is at 160 Robinson Road, #05-01 SBF Centre Medical Suites, Singapore 068914, in the CBD, a short walk from Tanjong Pagar, Shenton Way and Telok Ayer MRT stations.
Selected references
- Fecal Microbiota Transplantation. StatPearls, NCBI Bookshelf.
- Clostridioides difficile Infection. StatPearls, NCBI Bookshelf.
- US Food and Drug Administration. Safety alerts on fecal microbiota transplantation and transmission of pathogenic organisms.
- Irritable Bowel Syndrome. StatPearls, NCBI Bookshelf.
This page is educational and does not replace individual medical assessment. Evidence for faecal microbiota transplantation is strongly indication-specific and is well established only for recurrent C. difficile infection. Donor-derived material carries infection risk that screening reduces but cannot eliminate. Gastrointestinal red-flag symptoms require investigation rather than microbiome-directed treatment. Content reviewed by the medical team at Aquila Medical Center, Singapore. Last reviewed: 26 August 2026.
Start with the diagnosis, not the microbiome label
A consultation can help decide whether microbiome-directed care is reasonable, investigational, unnecessary, or whether another gastrointestinal work-up should come first.
For most symptoms, the honest answer is that investigation and diet will do more than a transplant — and we will say so.